product name Aztreonam
Description: Aztreonam (also known as SQ 26776) is a synthetic monocyclic beta-lactam antibiotic, used to treat Gram-negative aerobic bacteria infection. Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange.
References: J Antimicrob Chemother. 1991 Jan;27(1):95-104; J Antibiot (Tokyo). 1990 Apr;43(4):403-10; J Antimicrob Chemother. 2012 Nov;67(11):2673-81.
435.43
Formula
C13H17N5O8S2
CAS No.
78110-38-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 87 mg/mL (199.8 mM)
Water: 11 mg/mL (25.26 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
SQ 26776
other peoduct :
| In Vitro |
In vitro activity: Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange. Aztreonam is extremely stable as to the typical class C cephalosporinase of Citrobacter freundii, and acts as a competitive and progressive inhibitor for the beta-lactamase. Aztreonam (AZT) combined with clindamycin (CLDM) has synergistic effects on Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Haemophilus influenzae, which are sensitive or quasi-sensitive to CLDM, in the presence of CLDM at MIC or sub-MIC. Aztreonam reduces the cfu of some strains by 1 log unit without preserving the integrity of cystic fibrosis airway cell monolayers, while decreasing the biofilms of other clinical isolates by 4 log units and protecting the monolayers from being compromised. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Aztreonam (300 mg/kg) results in a significant decrease in the content of hepatic microsomal P450, while no significant change is observed in hepatic cytochrome b5 content and NADPH-cytochrome c (P450) reductase activity. |
| Animal model | |
| Formulation & Dosage | |
| References | J Antimicrob Chemother. 1991 Jan;27(1):95-104; J Antibiot (Tokyo). 1990 Apr;43(4):403-10; J Antimicrob Chemother. 2012 Nov;67(11):2673-81. |
